InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.00%
)
US TECH 100
18,932.80
(
-0.42%
)
Dow Jones
41,393.78
(
0.00%
)
Brent Oil
71.93
(
0.76%
)
Bitcoin
58,613.60
(
-0.95%
)
Post# of 253125
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120436
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 126552

Friday, 05/03/2013 5:41:01 PM

Friday, May 03, 2013 5:41:01 PM

Post# of 253125
TEVA/MNTA—In scanning some old posts, I came across yet another instance of misdirection by Teva’s Bill Marth (who is no longer with the company). Marth said as recently as late 2011 that Teva was still developing the “low volume” formulation of Copaxone: #msg-67094037. We know now that this program is dead, and it was probably dead even then.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up